Agenus has been granted a Type B End-of-Phase 2 meeting from the U.S. FDA

Agenus shared on LinkedIn:

“Today we announced that Agenus has been granted a Type B End-of-Phase 2 meeting from the U.S. FDA to discuss our botensilimab/balstilimab therapy for relapsed or refractory metastatic colorectal cancer.